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efficiency of pemetrexed-ionizing radiation 
combination therapy elicits a differential DNA 
damage response in lung cancer cells
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Abstract 
Background: Lung cancer causes the most cancer deaths worldwide, thus there is a urgent need to develop new 
treatment options. Concurrent chemoradiotherapy has become a common strategy for the treatment of non‑
resectable solid tumors including non‑small cell lung cancer. Pemetrexed is a folic acid antagonist that inhibits the 
synthesis of precursor nucleotides, whereas ionizing radiation induces DNA damage, the repair of which is dependent 
on sufficiently high nucleotide levels. In the clinical setting, the pemetrexed‑ionizing radiation combination therapy is 
administered concomitantly. We hypothesized that prolonged pretreatment with pemetrexed could be beneficial, as 
prior depletion of nucleotide pools could sensitize cancer cells to subsequent irradiation.
Methods: Non‑small cell lung cancer A549 cells were treated with 1 µM pemetrexed for 72 h. In addition, cells 
were exposed to five gray ionizing radiation either 1, 48 or 71 h after the initiation of the pemetrexed treatment. Cell 
growth, senescence induction, cell cycle distribution and DNA damage marker accumulation were analysed at differ‑
ent time points during the treatment and the recovery phase.
Results: Stand‑alone treatments of five gray ionizing radiation and 1 µM pemetrexed resulted in an intermediate 
cell growth inhibition of A549 cells and were therefore applied as the combination regimen. Prolonged pemetrexed 
pretreatment for 71 h resulted in a significant S‑phase accumulation. Irradiation and prolonged pemetrexed pretreat‑
ment maximally delayed long term cell growth. Additionally, senescence was augmented and recovery from treat‑
ment‑induced DNA damage was most prominently delayed by prolonged pemetrexed pretreatment.
Conclusions: Pretreatment with pemetrexed increases anticancer efficiency of pemetrexed‑ionizing radiation 
combination therapy, which correlates with a persistence of treatment‑induced DNA damage. Therefore, this study 
warrants further investigations to elucidate whether a similar adaptation to the standard treatment regimen could 
enhance the effectiveness of the non‑small cell lung cancer clinical treatment regimen.
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Background
Lung cancer is the leading cause of cancer-related mor-
tality, resulting in over 1 million deaths worldwide each 
year. This is partly due to the difficulty in detecting the 
disease at early and more treatable time points, and a 
lack of effective treatment methods. Non-small cell lung 
cancer (NSCLC) accounts for approximately 85  % of all 
lung cancers, and approximately one-third of patients 
present with locally advanced NSCLC. For these patients, 
curative treatment is a challenge since the majority 
have unresectable bulky disease or extensive mediasti-
nal lymphadenopathy resulting in a low 5-year survival 
rate (reviewed in [1]). For patients with locally advanced 
unresectable disease, concurrent chemoradiotherapy is 
considered the standard therapeutic approach (reviewed 
in [2]). However, the optimal chemotherapy regimen 
for use in conjunction with concurrent thoracic radio-
therapy (RT) is still under debate. The combination of 
pemetrexed (multitargeted antifolate, MTA; commercial 
name ‘Alimta’) with cisplatin was recently recommended 
as the gold standard therapy for adenocarcinoma lung 
cancer patients with good performance status [3]. Two 
clinical trials evaluated single-agent MTA plus RT with-
out consolidation therapy concluded that MTA can be 
given at full dosages during RT (reviewed in [2]). MTA is 
a folic acid antagonist inhibiting the synthesis of precur-
sor purine and pyrimidine nucleotides that are required 
for DNA and RNA synthesis. MTA thereby interferes 
with the proliferation and survival of replicating cancer 
cells. Prolonged treatment with MTA induces replicative 
stress in the form of single stranded DNA, which, if not 
repaired, can lead to the formation of DNA double strand 
breaks (DSB) [4]. Ionizing radiation (IR) induces exten-
sive base damage and creates DNA single strand breaks, 
resulting in DSB formation when two single strand nicks 
are present in complementary DNA strands within one 
helical turn (reviewed in [5]). DSBs are amongst the most 
cytotoxic DNA lesions, activating cell death response if 
unrepaired, and promoting genome instability if mis-
repaired (reviewed in [6]). DNA repair synthesis is a 
crucial step common to the various DSB repair mecha-
nisms, and it has been proposed that the availability of 
nucleotide substrates for DNA repair synthesis may be a 
limiting factor for DSB repair [7]. Indeed, MTA pretreat-
ment for up to 24 h prior to irradiation has been shown 
to enhance radiation-induced inactivation of lung carci-
noma cells in  vitro [8, 9]. We have recently shown that 
prolonged MTA pretreatment for 48 h augments persis-
tence of cisplatin-induced DNA damage and eliminates 
resistant lung cancer cells (Tièche et  al., manuscript in 
preparation). Thus in the present study, we hypothesized 
that prolonged pretreatment with pemetrexed could 
also be beneficial to radiation-induced therapy, as prior 
depletion of nucleotide pools could similarly sensitize 
cancer cells to subsequent irradiation.
In this study, we optimized MTA-IR anticancer treat-
ment modality, and performed an in-depth molecular 
and cellular analysis to elucidate the molecular mecha-
nisms underlying the observed benefit of sequential com-
bination therapy. We demonstrated that prolonged MTA 
pretreatment improved the combination therapy’s effi-
ciency. This effect correlated with the induction of persis-
tent DNA damage and senescence initiation.
Methods
Cell culture and reagents
The NSCLC cell line A549 was cultured in Dulbecco’s’ 
modified Eagle’s medium nutrient mixture F-12 Ham 
(Cat. #D6421, Sigma-Aldrich, St. Louis, MO, USA), sup-
plemented with 10  % fetal bovine serum (Cat. #10270-
106; Life Technologies, Grand Island, NY, USA), 1  % 
penicillin/streptomycin solution (Cat. #P0781, Sigma-
Aldrich) and 1  % l-glutamine (Cat. #25030-024, Sigma-
Aldrich) at 37 °C in a humidified 5 % CO2 incubator. The 
cell line was previously DNA fingerprinted (Microsynth, 
Bern, Switzerland). Medium was changed every 3 days.
Pemetrexed/MTA (commercial name ‘ALIMTA’; Cat 
#VL7640) was purchased from Eli Lilly (Suisse) S.A. 
(Vernier/Geneva, Switzerland).
Drug response and senescence associated β‑galactosidase 
assay
To determine cell growth during the treatment and the 
initial recovery phase, 0.2  ×  106 cells were seeded into 
150  mm  ×  20  mm tissue culture treated plates (Cat. 
#20151, SPL Life Sciences Co., Ltd, Korea). Starting at 
the day after seeding, i.e. day 0, cells from one plate per 
treatment were harvested using TrypLE (Cat. #12604021, 
Invitrogen, Grand Island, NY, USA). Cell titers were 
determined using a hemocytometer and trypan blue 
(Sigma-Aldrich) (final concentration 0.1 %) for dead cell 
exclusion. The cells were washed in phosphate-buffered 
saline and processed for analysis by flow cytometry as 
described below. To determine cell growth during the 
extended recovery period, cells were harvested at day 
9 of the recovery period, reseeded at a 1:10 ratio into 
150 mm × 20 mm plate. At day 13, cells were harvested 
and the titer was determined as described above, the 
subsequent flow cytometric analysis was performed as 
described below. Experiments were repeated indepen-
dently three times.
Senescent cells were visualized by using the senes-
cence associated β-galactosidase assay (Cat. #20151, Cell 
Signaling Technology, MA, USA). In detail, at day 6 after 
each treatment cells were fixed and stained overnight 
according to the manufacture’s protocol. An inverted 
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light microscope (Eclipse TS100, Nikon Instruments Inc., 
Melville NA, USA) equipped with a 10× objective was 
used for visual quantification of senescent cells. Experi-
ments were repeated independently three times.
Flow cytometry
For analysis by flow cytometry, cells were harvested as 
described above. Subsequently, cells were washed with 
phosphate-buffered saline, pH 7.4, fixed and permeabi-
lized with Cytofix/Cytoperm solution [Cat. #554714, BD 
Biosciences (San Jose, CA, USA)]. Staining with mouse 
Alexa Fluor 488 anti-γH2AX (Ser139) (Cat. #613406, 
Bio Legend, San Diego, CA, USA) antibody was per-
formed in phosphate-buffered saline (Pharmacy, Univer-
sity Hospital Bern, BE, Switzerland) supplemented with 
0.5  % saponin (Sigma-Aldrich) and 1  % bovine serum 
albumin (Sigma-Aldrich) on a rotating wheel (3 revolu-
tions per minute) overnight at 4  °C. Subsequently, cells 
were treated with 100  µg/ml RNase A (Sigma-Aldrich) 
and DNA was stained simultaneously with 0.5  µg/ml 
4′,6-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich). 
Cell fluorescence was measured on a LSR2 upgraded flow 
cytometer (BD Biosciences) and analyzed using FlowJo 
V10 [Tree Star, Inc. (Ashland, OR, USA)]. Samples from 
the different time points were stored at 4  °C and flow 
cytometric analysis of all samples from one experiment 
was subsequently performed in parallel. Each analysis 
was accompanied by an untreated control. Buffer treated 
controls were used to set the gating threshold for γH2AX 
positivity to ~10 % of the total cell population as describe 
before [10].
Statistical analysis
Data are presented as the mean ± standard deviation of 
at least three independent experiments if not stated dif-
ferently. Data was analyzed using Excel software. Statisti-
cal differences were assessed using unpaired t test with 
Welch’s and P values <0.05 were considered significant.
Results
Optimization of the chemoradiotherapy treatment 
schedule increases anticancer efficacy
In order to optimize the treatment schedule of MTA plus 
irradiation, the concentration of MTA and level of expo-
sure to irradiation that induced an intermediate level of 
growth inhibition was determined. Exposure to 5 Gy IR 
or treatment with 1 µM MTA resulted in an intermediate 
reduction of cell numbers (Additional file  1: Figure S1; 
Fig.  1b) and these conditions were therefore applied to 
the combination therapy. Three different treatment regi-
mens were compared to determine whether the effective-
ness of the MTA-IR combination therapy is dependent 
on the treatment schedule, including continuous MTA (1 
μM) treatment for 72 h combined with exposure to 5 Gy 
IR at different time points (Fig. 1a). In detail, cells were 
irradiated 1, 48 or 71  h after the initiation of the 72  h 
MTA treatment (treatment #1, #2 or #3, respectively). 
The doubling time (day 0➙3) of untreated A549 cells was 
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Fig. 1 Optimization of the treatment schedule potentiates MTA‑irra‑
diation anticancer efficacy. a Schedule of the three tested treatment 
regimens differing in the duration of MTA pretreatment preceding 
irradiation. See text for details. b Growth curves of A549 cells during 
the treatment (0–3 days) and early recovery phase (up to 6 days 
post‑treatment, e.g. day 9). c Cells exposed to the indicated treatment 
regimen were harvested at day 9 of the recovery phase, reseeded 
and cell numbers were determined at day 13 points. Data represent 
means of three independent experiments and bars indicate standard 
deviations. *P < 0.05
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found to be approximately 22 h (Tièche et al., manuscript 
in preparation), which is in agreement with the informa-
tion provided by the American Type Culture Collection. 
Compared to the untreated control, cell growth slightly 
decreased after 24  h MTA treatment alone (treatments 
#2 and #3, day 1) and further decreased after either 48 or 
71 h MTA alone (treatment #3, day 2 or 3 respectively) 
(Fig.  1b). When the IR treatment was applied 1  h after 
the start of the MTA treatment (treatment #1), cell num-
bers did not increase considerably during the subsequent 
24 h. In contrast, after pretreatment with MTA-for 48 h, 
cell numbers steadily increased during the 24  h follow-
ing irradiation (treatment #2, day 2➙3). At the end of 
the treatment phase (day 4), the absolute cell counts were 
significantly lower after treatment #1 compared to treat-
ment #2 and #3. However, during the extended recov-
ery phase (day 6➙9), cell numbers steadily increased 
after treatment #1 whereas cell growth was significantly 
decreased after treatment #2 compared to treatment #1 
and were further reduced after treatment #3 (Fig.  1b). 
In detail, during the recovery phase (day 6➙9) the dou-
bling time of recovering cells after treatment #1 was 83 h 
whereas treatment #3 significantly prolonged the dou-
bling time of the recovering cells (176 h) and with treat-
ment #2 inducing an intermediate level of growth delay 
(116  h). To evaluate the growth capacity of the remain-
ing cells, the residual cells were harvested at day 9 of the 
recovery phase and reseeded at low density. At day 13 
of the recovery phase, cell numbers compared to treat-
ment #1 were 1.9 and 2.9 times lower after treatments #2 
and #3, respectively (Fig. 1c). Thus, treatment #3 reduced 
overall survival by a factor of ~7 compared to treatment 
#1 (fold difference in cell number at day 9 multiplied 
by day 13, i.e. 2.4 × 2.9). In other words, long-term cell 
growth was significantly reduced after extended pretreat-
ment when compared to concomitant treatment.
Prolonged MTA pretreatment and subsequent irradiation 
induces senescence
Prolonged cell cycle arrest after DNA damage induction 
results at the molecular level in DNA double strand break 
formation and at the cellular level in a terminal prolifera-
tion halt, i.e. senescence [11]. By permanently arresting 
proliferation of damaged cells, senescence serves as a 
barrier to cancer development.
Visual examination of the recovered cells after treat-
ment #1 revealed that clones formed by small, cuboid 
cells could be distinguished from surrounding cells, 
which displayed morphologic changes that are associated 
with senescence, namely increased cell size and flattened 
shape (Fig.  2a; reviewed in [12]). The fraction of cells 
featuring a senescence phenotype was increased after 
treatment #2 and maximized after treatment #3 (Fig. 2a). 
Cells were stained to detect senescence-associated 
β-galactosidase (SA-β-Gal) activity. At day 6, the fraction 
of SA-β-Gal-positive cells (indicated by blue staining in 
Fig. 2a) was 4.5-fold higher after treatment #3 compared 
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Fig. 2 Prolonged MTA pretreatment augments irradiation‑induced 
senescence in A549 cells. a Representative images of cells acquired 
by phase contrast‑based microscopy at day 6. b Quantification of 
senescent cells based on increased β‑galactosidase activity (see 
Fig. 2a). Data represent means of two independent experiments and 
bars indicate means and standard deviations. *P < 0.05. c Forward 
and side scatter analysis was performed by flow cytometry at the 
indicated time points. Data shown are the mean values and standard 
deviations of three independent experiments
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to treatment #1 (Fig.  2b, P  >  0.05). Detectable by flow 
cytometry, increased forward (cell size) and side (cellular 
granularity) scatter intensity (F/S-high) is an additional 
feature associated with senescence (reviewed in [13]). 
Flow cytometric analysis at day 9 of the recovery phase 
revealed that the highest frequency of cells with a F/S-
high phenotype was observed after treatment #3 (Fig. 2c). 
In detail, compared to the untreated control (13.3 %), the 
frequency of F/S-high cells was 1.5 and 3.3-fold higher 
after treatment #1 and treatment #3, respectively (19.8 
and 43.2 %, P > 0.05), with treatment 2 inducing an inter-
mediate level of senescence. Nevertheless, flow cytomet-
ric analysis at the end of the treatment phase (day 3) and 
during the early recovery phase (day 6) confirmed that for 
all three treatments, a fraction of the cells maintained a 
normal forward and side scatter intensity (F/S-low), indi-
cating the presence of cells resistant to the tested treat-
ment regimens (Additional file  2: Figure S2). However, 
compared to treatment #1, treatment #3 significantly 
decreased the fraction of resistant cells, e.g. F/S-low cells, 
indicating that extended MTA pretreatment can augment 
the anticancer activity of radiation therapy.
Prolonged MTA pretreatment enhances S‑phase 
accumulation prior to irradiation
Terminal cell cycle arrest is a classic hallmark of senes-
cence, and has been observed after treatment with chem-
otherapy (reviewed in [12]). Therefore, we monitored the 
cell cycle distribution of A549 cells during and after com-
bined MTA-IR treatment (Fig. 3). MTA-alone treatment 
for 24 h did not result in a significantly changed cell cycle 
distribution (treatment #2 or 3, day 1). MTA-alone treat-
ment for 48  h increased the fraction of cells in S-phase 
(treatment #3, day 2), which was even more pronounced 
after 72 h (treatment #3, day 3). Thus, at the start of the 
irradiation during treatment #1 (day 0), the cells mainly 
resided in the G1-phase of the cell cycle. In contrast, 
at the start of irradiation during treatment #2 (day 2), 
a significant fraction of the cells (37  %) was arrested in 
S-phase, which was further increased at the start of the 
irradiation during treatment #3 (day 3, 47 %).
Interestingly, when irradiation was preceded by MTA 
pretreatment for 48  h, the fraction of cells in S-phase 
decreased during the 24 h after irradiation (treatment #2, 
day 2 compared to day 3). An adverse effect of irradiation 
on the subsequent MTA-induced S-phase accumulation 
was also detectable after concurrent therapy. In detail, 
concurrent irradiation (treatment #1, day 0) completely 
abolished the MTA-induced S-phase accumulation at 
the end of the treatment phase (day 3, treatment #1 com-
pared to treatment #3).
The cell cycle distribution of the recovering culture 
was normal during the early recovery phase (day 3➙6) 
after treatment #1. Since treatment #1 did not result in 
pronounced growth retardation, the cell culture became 
confluent during the later recovery phase (day 9) as also 
indicated by the accumulation in the G1-phase. Reseed-
ing at low density revealed that the cell culture acquired a 
normal cell cycle distribution during the extended recov-
ery phase, which was also detectable after treatment #2 
and #3 (day 13). A sub-G1 DNA content is a hallmark of 
cells undergoing apoptosis. A very small fraction of sub-
G1 cells (1.4 %) was observed 24 h after irradiation dur-
ing treatment #1 (day 2) but not after treatment #2 (day 
3) and also not 3  days after treatment #3 (day 6) indi-
cating that the tested treatment regimen did not result 
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in significant induction of apoptosis. In summary, pre-
treatment with MTA for a prolonged period enhanced 
S-phase accumulation prior to irradiation. However, this 
effect was transitory in the remaining, therapy-resistant 
fraction of the cells and cell growth returned to normal 
during the extended recovery phase.
Prolonged MTA pretreatment results in persistent DNA 
damage accumulation
Induction of DNA breaks or DNA replication stress leads 
to the activation of the DNA damage response (DDR) 
(reviewed in [14]). During DDR, phosphorylation of his-
tone variant H2AX (γH2AX) serves as a key mediator for 
the assembly of DNA repair proteins at the sites of DNA 
damage as well as for the activation of checkpoint pro-
teins. Consequently, analysis of γH2AX is frequently used 
as a surrogate marker for DDR activation.
We have previously demonstrated that accumulation 
of persistent DNA damage leads to a cell cycle arrest 
and induction of senescence in A549 cells [15]. Thus, we 
determined the effect of the different treatment regimens 
on H2AX phosphorylation. Analysis of the total popu-
lation revealed that irradiation with 5 Gy IR resulted in 
phosphorylation of H2AX in more than 90 % of the cells 
irrespective if MTA was administered concomitantly or 
as pretreatment (Fig. 4a). MTA-alone treatment for 24 h 
only marginally increased γH2AX levels in the total pop-
ulation (treatments #2 and 3, day 0➙1) (Fig. 4a). How-
ever, analysis of the cell cycle specific subpopulations 
revealed that MTA-alone treatment slightly increased 
γH2AX levels in S-phase and G2/M-phase cells whereas 
cells in the G1-phase were not affected (Fig.  4b). MTA 
treatment for 48 h (treatment #3, day 2) resulted in robust 
H2AX phosphorylation in a fraction of S-phase cells 
(34 %), which was also observed in the majority of cells 
in the G2/M-phase (66 %). After MTA-IR co-treatment, 
H2AX was rapidly phosphorylated in the majority of cells 
in all cell cycle phases (93 % of total population) (treat-
ment #1, day 1, Fig.  4a). 24  h after irradiation, γH2AX 
phosphorylation returned to basal levels even in the pres-
ence of MTA co-treatment (treatment #1, day 0➙1). 
Similarly, H2AX phosphorylation was increased to nearly 
maximal levels in all phases of the cell cycle when irra-
diation was preceded by 48 or 71  h MTA pretreatment 
(91 and 97  % of total population, respectively) (treat-
ment #2, day 2 and treatment #3, day 3, respectively). 
H2AX phosphorylation also returned to basal levels 24 h 
after irradiation during treatment #2 (treatment #2, day 
2➙3). However, H2AX phosphorylation levels were still 
increased 3 and 6  days after termination of treatment 
#3 (day 6 and 9, respectively) compared to treatment #1 
(25.7 and 20.5 % for treatment #3 compared to 16.5 and 
6.0  % for treatment #1, respectively, P  <  0.05) (Fig.  4a). 
During the recovery phase after treatment #3 (day 9), 
only a small fraction of cells in the G1-phase contained 
high levels of H2AX phosphorylation whereas persistent 
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H2AX phosphorylation was detectable in the majority of 
cells in the G2/M-phase, which was absent after treat-
ment #1 (Fig. 4b). In summary, prolonged MTA pretreat-
ment (treatment #3) increased H2AX phosphorylation 
levels during the extended recovery phase.
In summary, the inhibitory effect of MTA-IR combina-
tion therapy on lung cancer cell growth can be further 
augmented by the optimization of the treatment sched-
ule. Prolonged MTA pretreatment preceding irradiation 
reduces cell growth compared to concomitant treatment 
and increases the fraction of senescent cells. In addi-
tion, extended MTA-pretreatment induces a pronounced 
S-phase accumulation, which is abrogated by concomi-
tant IR treatment. Finally, our investigations reveal that 
prolonged MTA pretreatment significantly delays recov-
ery after DNA damage induction.
Discussion
Concurrent chemoradiotherapy is considered the 
standard therapeutic approach for patients with locally 
advanced unresectable NSCLC. It is used for early treat-
ment of micrometastatic disease and exploits the syner-
gistic effect of the combination therapy in the shortest 
possible time frame (within several weeks), which 
explains its superiority compared to sequential therapy, 
i.e. several weeks of chemotherapy followed by radiation 
therapy (reviewed in [2]). The aim of the present study is 
the exploration of schedule-dependent effects within the 
concurrent MTA-IR combination therapy. The present 
in vitro study provides evidence to suggest that pretreat-
ment with MTA prior to irradiation is significantly more 
efficient than concomitant treatment. These results are 
in agreement with previous studies showing that MTA 
pretreatment up to 24 h enhanced the radiation-induced 
inactivation of lung carcinoma cells in  vitro [8, 9]. In 
a recent study, we demonstrated that prolonged MTA 
pretreatment for 48 h augments persistence of cisplatin-
induced DNA damage and eliminates resistant lung 
cancer cells (Tièche et  al., manuscript in preparation). 
Similarly, 24  h pretreatment with MTA sensitized A549 
cells to a subsequent treatment with a histone deacety-
lase inhibitor and increased the survival-benefit of the 
combination treatment in a patient-derived lung cancer 
mouse xenograft model [16]. Thus, the present results 
are in agreement with the general consensus in the litera-
ture indicating that MTA pretreatment sensitizes NSCLC 
cells to a variety of cytotoxic drugs and treatments. The 
present study provides for the first time an in-depth anal-
ysis of the effects on NSCLC cells of the combined treat-
ment of MTA and irradiation over an extended recovery 
period.
At end of the treatment phase (day 3), cell numbers 
were twofold lower after treatment #1 compared to 
treatment #3. Thus, a short-term analysis would there-
fore suggest treatment #1 to be the most efficient of the 
tested treatment regimens. However, treatment #3 was 
more effective over an extended recovery period. Tumor 
growth in animal models is usually monitored over peri-
ods of several weeks. Thus, it is tempting to speculate 
that tumor formation might be modelled in  vitro more 
closely by the long-term growth analysis compared to 
a short-term study. However, further in vivo studies are 
needed to demonstrate the superior anticancer efficiency 
of pretreatment with MTA prior to ionizing radiation.
Although increased senescence was observed 
after treatment #1, as demonstrated by increased 
β-galactosidase activity, cell size and granularity, these 
senescence-associated effects were much more pro-
nounced after treatment #3. Consistent with our find-
ings of senescence induction, it has been shown that 
MTA-treated malignant mesothelioma cells also undergo 
accelerated senescence [17]. Senescent cancer cells can 
be cleared by the immune system, however the role of 
senescence in cancer progression is still controversial 
(reviewed in [12]). Senescence serves as a physiological 
barrier against tumor initiation and progression. On the 
other hand, senescent cancer cells might be able to over-
come their dormant state, thus representing a dangerous 
potential for tumor relapse. It will therefore be crucial to 
utilize an immune competent animal model to determine 
the schedule-dependent anticancer efficiency of the com-
bination therapy.
It is well established that the cell cycle status plays a 
critical role in the efficiency of combination chemother-
apy. Unperturbed cells are maximally sensitive to treat-
ment with IR during late G1/early S-phase and least 
sensitive during the peak of DNA synthesis in S-phase 
[18]. However, it has been shown that pretreatment of 
human colon carcinoma cells with the pemetrexed ren-
dered not only G1-phase cells but also S-phase cells more 
sensitive to irradiation [19]. We showed that treatment 
with 1 µM MTA alone for 48 h resulted in the accumu-
lation of cells in S-phase, which is in agreement with a 
previous study [20]. At the start of the irradiation, the 
fraction of cells in S-phase was highest in treatment #3 
(day 3) compared to treatment #2 (day 2) and treatment 
#1 (day 1). Thus, we observed increased radiation sensi-
tivity upon MTA-induced S-phase arrest, suggesting that 
it is not the S-phase status per se but is more likely to be 
the MTA-induced perturbation of DNA synthesis, which 
sensitizes cells to subsequent treatment with IR. Indeed, 
it has been reported that cells blocked at the G1/S-
boundary remained sensitive to DNA damage induction 
after release of the block [21].
It was shown that the MTA-induced S-phase arrest 
in A549 cells relies on increased Cdk2/cyclin-A kinase 
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activity, which itself was dependent on ERK-signaling 
pathway activity [20]. A subsequent study confirmed 
that the S-phase arrest upon MTA treatment in A549 
cells is dependent on sustained Cdk2/cyclin-A activation 
although in this study, prolonged activation was found to 
be dependent on the PI3K/Akt signaling pathway [22]. 
Thus, the current literature indicates that the observed 
S-phase arrest upon MTA treatment is regulated by the 
complex interplay between various upstream signaling 
pathways. The dissection of this multifaceted signaling 
network will require an extensive analysis, ideally on the 
whole-genome transcriptome/(phospho-)proteome scale. 
Although beyond the scope of this study, this analysis 
might lead to the identification of targets and subse-
quently inhibitors with the potential to synergistically 
enhance the activity of the MTA-IR combination therapy.
Absolute cell numbers were significantly reduced 
6 days after treatment #3 (day 9) compared to treatment 
#1, which was also observed after an extended recovery 
phase (day 13) (Fig. 1). However, comprehensive analysis 
revealed that at day 3 of the recovery phase (day 6) the 
cell cycle distribution of the remaining cells was similar 
to the untreated control (Fig.  3) indicating that at least 
a fraction of the recovering cells were proliferating. In 
summary, during the extended recovery period, a sub-
population of cells in all three treatment groups over-
came cell cycle arrest and successfully completed mitosis, 
as also indicated by the increase of cells in the G1-phase 
at later recovery time points. Thus, this small fraction 
of cells is resistant to even the most efficient treatment 
regimen tested in this study, even though it is smaller in 
number than for other treatments.
Concomitant MTA-IR treatment of A549 cells led to a 
significant increase in H2AX phosphorylation, a marker 
for activation of the DNA damage response. Interestingly, 
similar γH2AX levels were reached when the radiation 
treatment was preceded by MTA pretreatment for 48 or 
71 h, respectively. In other words, MTA pretreatment did 
not diminish H2AX phosphorylation upon IR-induced 
DNA damage formation. Furthermore, after MTA pre-
treatment for 48 h and concomitant MTA-IR treatment 
for 24 h, H2AX phosphorylation levels were only slightly 
increased compared to the untreated control. This sug-
gests that the tested MTA treatment regimen (1  µM, 
48  h) did not decreased cellular nucleotide levels to an 
extent that abolishes the repair of the IR-induced DNA 
damage. However, significantly higher γH2AX phospho-
rylation levels was observed during the recovery phase 
after treatment #3, in which irradiation was preceded by 
an extensive MTA pretreatment (3 days) indicating that 
prolonged MTA treatment might be required to aug-
ment the anticancer effect of the IR treatment. Indeed, 
we observed a significant increase in S-phase cells after 
3 days compared to 2 days of MTA pretreatment, which 
was accompanied by increased H2AX phosphoryla-
tion in S-phase cells. It has been shown previously that 
nucleotide depletion leads to stalled replication forks, 
which progressively become inactivated and require 
two different RAD51-mediated pathways for restart and 
repair [23]. During S-phase, non-homologous end join-
ing is repressed and DSBs are repaired by the RAD51-
dependent homologous recombination pathway. Thus, 
we hypothesize that MTA-induced nucleotide depletion 
induces the sequestration of RAD51 to stalled or col-
lapsed replication forks. Insufficient RAD51 levels limit 
the repair of IR-induced DNA DSBs by RAD51-depend-
ent homologous recombination pathway resulting in the 
formation of complex DNA repair intermediates and the 
subsequent persistence of H2AX phosphorylation. How-
ever, further experiments will be required to elucidate the 
exact molecular mechanisms involved.
It has been previously demonstrated that treatment 
with 5-fluorouracil leads to the incorporation of 5-fluo-
rouracil and uracil during S-phase, generating DNA 
repair-dependent, persistent DNA strand breaks during 
the successive G2/M-G1-phase, thereby interfering with 
the replication machinery in the subsequent S-phase 
[24]. The increased levels of H2AX phosphorylation at 
the extended recovery time points after treatment #3 
therefore might be due to the persistence of complex 
DNA damage or repair intermediates. In this context, it 
has been shown previously that the persistence of H2AX 
phosphorylation 24 h after cisplatin treatment was asso-
ciated with the loss of clonogenicity [25]. In summary, the 
analysis of H2AX phosphorylation levels have provided 
a first insight into the molecular mechanisms underly-
ing the increased efficiency of the combination therapy 
after prolonged MTA pretreatment. Further studies will 
be necessary to elucidate the exact nature of the resulting 
DNA damage after prolonged MTA pretreatment.
Our study was restricted to the analysis of the cell line 
A549 featuring an activating mutation of the KRAS onco-
gene. In lung adenocarcinoma, oncogenic KRAS muta-
tions are highly prevalent (~25 %) but therapy choices are 
very limited (reviewed in [3]) suggesting that our findings 
might be of relevance to advance treatment of a signifi-
cant fraction of lung adenocarcinoma patients. However, 
further analysis of cell lines and primary cultures con-
taining alternative mutational signatures will be neces-
sary to evaluate if these findings are also of relevance for 
different lung cancer subsets.
MTA is administered as a daily 10-min infusion, 
which results in a relative rapid clearance from the body. 
However, MTA is efficiently converted intracellularly 
to an active polyglutamate form. Thus, although MTA 
blood levels decline rapidly, active MTA polyglutamate 
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derivatives are sustained in tumor cells explaining the 
clinical efficiency of the initial phase I trials with single-
agent MTA therapy, which was administered on day 1 
every 21 days for up to six cycles (reviewed in [26]). The 
present study reveals that prolonged MTA pretreatment 
increases the efficiency of the combination MTA-IR ther-
apy in vitro. Hence, it is tempting to speculate that a delay 
of the irradiation might also increase the efficiency of the 
MTA-IR combination therapy in the clinical setting.
Conclusions
The present study has revealed that the efficiency of the 
MTA-IR combination therapy can be augmented in vitro 
by modifying the treatment schedule to include pro-
longed MTA pretreatment. The increased efficiency of 
this treatment can be attributed to the induction of per-
sistent DNA damage, which in turn results in increased 
senescence initiation. Therefore, our study warrants fur-
ther experiments to elucidate whether an optimization of 
the standard therapy schedule might also potentiate the 
current MTA-IR combination treatment regimen in vivo.
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